
Quarterly report 2022-Q4
                    added 02-09-2023
Cardiovascular Systems Financial Statements 2011-2025 | CSII
Annual Financial Statements Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | 
                            
                            588 M | 815 M | 1.41 B | 1.54 B | 1.11 B | 1.03 B | 638 M | 943 M | 809 M | 427 M | 167 M | 238 M | 
                            
                                Shares | 
                            
                            39.2 M | 38.8 M | 34.3 M | 33.5 M | 33.1 M | 32.4 M | 32.5 M | 31.5 M | 28.3 M | 21.7 M | 18 M | 15.9 M | 
Historical Prices | 
                            
                            15.3 | 21.1 | 41.3 | 37.6 | 35.4 | 23.8 | 28.4 | 8.36 | 37.7 | 35 | 15.8 | 9.05 | 
Net Income | 
                            
                            -36.9 M | -13.4 M | -27.2 M | -255 K | 1.71 M | -1.79 M | -56 M | -32.8 M | -35.3 M | -24 M | -16.8 M | -11.1 M | 
Revenue | 
                            
                            236 M | 259 M | 237 M | 248 M | 217 M | 205 M | 178 M | 182 M | 137 M | 104 M | 82.5 M | 78.8 M | 
Cost of Revenue | 
                            
                            63.4 M | 61.1 M | 48.8 M | 47.7 M | 39.5 M | 39.4 M | - | - | - | - | - | - | 
Gross Profit | 
                            
                            173 M | 198 M | 188 M | 200 M | 178 M | 165 M | 143 M | 142 M | 106 M | 79.5 M | 63.3 M | 62.5 M | 
Operating Income | 
                            
                            -35.8 M | -11.9 M | -26.8 M | -825 K | 2.23 M | -1.54 M | -56.1 M | -32.6 M | -33.5 M | -22.4 M | -14.5 M | -8.81 M | 
Interest Expense | 
                            
                            1.63 M | 1.74 M | 1.97 M | 1.68 M | 1.72 M | 500 K | - | 23 K | 1.03 M | 1.34 M | 1.36 M | 1.42 M | 
EBITDA | 
                            
                            -32.1 M | -8.84 M | -23.8 M | 2.62 M | 6.17 M | 2.59 M | -41.8 M | -30.3 M | -32.1 M | -21.4 M | -13.6 M | -8.09 M | 
Operating Expenses | 
                            
                            209 M | 210 M | 215 M | 201 M | 175 M | 167 M | 188 M | 175 M | 139 M | 102 M | 77.7 M | 71.3 M | 
General and Administrative Expenses | 
                            
                            171 M | 167 M | 170 M | - | - | - | - | - | - | - | 66.4 M | 62.4 M | 
All numbers in USD currency
Quarterly Income Statement Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
                            
                                Shares | 
                            
                            39.7 M | 39.6 M | 39.6 M | 39.3 M | 39.2 M | 39.1 M | 39.1 M | 38.9 M | 38.8 M | 38.7 M | 38.8 M | 34.1 M | 34.1 M | 33.9 M | 34.1 M | 33.9 M | 33.5 M | 33.4 M | 33.5 M | 33.4 M | 33.1 M | 33 M | 33.1 M | 32.7 M | 32.2 M | 33 M | 32.2 M | 33 M | 32.6 M | 32.2 M | 32.4 M | 32.2 M | 31.5 M | 31.3 M | 31.5 M | 31.3 M | 27.2 M | 24.8 M | 26 M | 21.5 M | 20.7 M | 17.7 M | 20.7 M | 20.4 M | 17.8 M | 17.5 M | 17 M | 17 M | 
Net Income | 
                            
                            -7.89 M | -10.6 M | -18.5 M | -9.66 M | -8.97 M | -8.62 M | -17.6 M | -8.62 M | -56 K | -2.08 M | -56 K | -2.89 M | -3.4 M | -3.4 M | -3.4 M | -5.78 M | 492 K | 492 K | 492 K | -2.89 M | -413 K | -1.98 M | -413 K | -1.98 M | 1.04 M | -1.86 M | 1.04 M | -1.86 M | -15.2 M | -13.3 M | -15.2 M | -13.3 M | -5.27 M | -8.22 M | -5.27 M | -8.22 M | -8.66 M | -7.29 M | -8.66 M | -7.29 M | -5.77 M | -12.2 M | -5.77 M | -5.21 M | -4.14 M | -3.86 M | -4.14 M | -3.86 M | 
Revenue | 
                            
                            61.5 M | 59.7 M | 121 M | 56.2 M | 59.1 M | 58.4 M | 118 M | 63.3 M | 64.2 M | 60.5 M | 64.2 M | 61.2 M | 68.3 M | 64.5 M | 68.3 M | 64.5 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 52.6 M | 49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Cost of Revenue | 
                            
                            18.5 M | 16.7 M | 35.2 M | 14.8 M | 18.1 M | 14.3 M | 32.4 M | 14 M | 13.9 M | 12.6 M | 13.9 M | 12.2 M | 13.7 M | 12.7 M | 13.7 M | 12.7 M | 11.5 M | 10.6 M | 11.5 M | 10.6 M | 9.5 M | 9.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 
Gross Profit | 
                            
                            43 M | 43 M | 86 M | 41.4 M | 41.1 M | 44.1 M | 85.1 M | 49.3 M | 50.2 M | 48 M | 50.2 M | 49 M | 54.6 M | 51.8 M | 54.6 M | 51.8 M | 48.7 M | 45.7 M | 48.7 M | 45.7 M | 43.1 M | 40.5 M | 43.1 M | 40.5 M | 40.9 M | 40.3 M | 40.9 M | 40.3 M | 33.3 M | 35.1 M | 33.3 M | 35.1 M | 35.4 M | 32.5 M | 35.4 M | 32.5 M | 25 M | 22.9 M | 25 M | 22.9 M | 19.4 M | 18 M | 19.4 M | 18 M | 15.2 M | 14.3 M | 15.2 M | 14.3 M | 
Operating Income | 
                            
                            -8.53 M | -10.9 M | -19.4 M | -9.65 M | -8.56 M | -8.12 M | -16.7 M | -5.65 M | 283 K | -1.66 M | 283 K | -2.74 M | -3.37 M | -5.93 M | -3.37 M | -5.93 M | 384 K | -2.97 M | 384 K | -2.97 M | -275 K | -1.75 M | -275 K | -1.75 M | 1.08 M | -1.87 M | 1.08 M | -1.87 M | -15.1 M | -13.2 M | -15.1 M | -13.2 M | -5.25 M | -8.19 M | -5.25 M | -8.19 M | -7.5 M | -6.85 M | -7.5 M | -6.85 M | -5.12 M | -5.21 M | -5.12 M | -5.21 M | -3.66 M | -3.1 M | -3.66 M | -3.1 M | 
Interest Expense | 
                            
                            404 K | 406 K | 810 K | 408 K | 409 K | 410 K | 819 K | 412 K | 412 K | 499 K | 412 K | 501 K | 500 K | 472 K | 500 K | 472 K | 422 K | 424 K | 422 K | 424 K | 430 K | 432 K | 430 K | 432 K | 46 K | - | - | - | - | - | - | 1 K | 6 K | 16 K | 22 K | 103 K | 564 K | 281 K | 564 K | 281 K | 345 K | 370 K | 345 K | 370 K | 279 K | 344 K | - | - | 
EBITDA | 
                            
                            -8.18 M | -10 M | -17.6 M | -9.3 M | -8.21 M | -7.16 M | -14.8 M | -5.34 M | 587 K | -933 K | 1.76 M | -2.4 M | -3.04 M | -5.19 M | -1.88 M | -5.19 M | 439 K | -2.17 M | 1.96 M | -2.17 M | -275 K | -758 K | 1.71 M | -758 K | 1.08 M | -910 K | 3.02 M | -910 K | -15.1 M | -12.3 M | -13.3 M | -12.3 M | -5.25 M | -7.82 M | -4.5 M | -7.82 M | -7.5 M | -6.55 M | -7.39 M | -6.82 M | -5.12 M | -5.17 M | -5.12 M | -5.21 M | -3.66 M | -3.06 M | -3.66 M | -3.1 M | 
Operating Expenses | 
                            
                            51.5 M | 53.9 M | 105 M | 51.1 M | 49.6 M | 52.2 M | 102 M | 54.9 M | 50 M | 49.6 M | 50 M | 51.7 M | 58 M | 57.8 M | 58 M | 57.8 M | 48.3 M | 48.7 M | 48.3 M | 48.7 M | 43.4 M | 42.2 M | 43.4 M | 42.2 M | 39.8 M | 42.2 M | 39.8 M | 42.2 M | 48.5 M | 48.3 M | 48.5 M | 48.3 M | 40.6 M | 40.7 M | 40.6 M | 40.7 M | 32.5 M | 29.7 M | 32.5 M | 29.7 M | 24.5 M | 23.2 M | 24.5 M | 23.2 M | 18.8 M | 17.4 M | 18.8 M | 17.4 M | 
General and Administrative Expenses | 
                            
                            41.6 M | 44.5 M | 86.1 M | 41.7 M | 40.4 M | 41.9 M | 82.3 M | 41.4 M | 40.1 M | 40.3 M | 40.1 M | 41.4 M | 46.9 M | 46.8 M | 46.9 M | 46.8 M | 41.1 M | 41.2 M | 41.1 M | 41.2 M | 37 M | 35.9 M | 37 M | 35.9 M | 34 M | 36.9 M | 34 M | 36.9 M | 41.3 M | 41.4 M | 41.3 M | 41.4 M | 32.6 M | 33.5 M | 32.6 M | 33.5 M | 27.5 M | 25.4 M | 27.5 M | 25.4 M | 20.4 M | 20 M | 20.4 M | 20 M | 15.7 M | 15.4 M | 15.7 M | 15.4 M | 
All numbers in USD currency
Main types of financial statements Cardiovascular Systems CSIIFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities. 
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
 - GAAP — Generally Accepted Accounting Principles used in the United States.
 - RAS — Russian Accounting Standards, used domestically in Russia.
 
Financial reporting Cardiovascular Systems plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
| 
              
              Dynatronics Corporation
               DYNT 
              
             | 
            
              $ 0.24 | 14.99 % | $ 929 K | ||
| 
              
              Aziyo Biologics
               AZYO 
              
             | 
            
              $ 1.48 | 1.37 % | $ 20.5 M | ||
| 
              
              Natus Medical Incorporated
               NTUS 
              
             | 
            
              $ 31.08 | 1.94 % | $ 1.05 B | ||
| 
              
              Lianluo Smart Limited
               LLIT 
              
             | 
            
              $ 9.22 | 24.59 % | $ 44.8 M | ||
| 
              
              Obalon Therapeutics, Inc.
               OBLN 
              
             | 
            
              $ 3.05 | -5.86 % | $ 30.6 M | ||
| 
              
              Neovasc 
               NVCN 
              
             | 
            
              $ 30.03 | - | $ 111 M | ||
| 
              
              Apollo Endosurgery
               APEN 
              
             | 
            
              $ 10.0 | - | $ 475 M | ||
| 
              
              Titan Medical 
               TMDI 
              
             | 
            
              $ 0.14 | -26.32 % | $ 19.6 M | ||
| 
              
              Insulet Corporation
               PODD 
              
             | 
            
              $ 320.45 | 2.38 % | $ 22.5 B | ||
| 
              
              Viveve Medical
               VIVE 
              
             | 
            
              $ 0.22 | -15.35 % | $ 1.71 M | ||
| 
              
              Invacare Corporation
               IVC 
              
             | 
            
              $ 0.66 | - | $ 24.7 M | ||
| 
              
              Quanterix Corporation
               QTRX 
              
             | 
            
              $ 5.33 | -0.28 % | $ 200 M | ||
| 
              
              Abiomed
               ABMD 
              
             | 
            
              $ 381.02 | - | $ 17.2 B | ||
| 
              
              AVITA Medical
               RCEL 
              
             | 
            
              $ 3.76 | -2.84 % | $ 97.3 M | ||
| 
              
              Allied Healthcare Products
               AHPI 
              
             | 
            
              $ 0.55 | 3.58 % | $ 2.21 M | ||
| 
              
              CHF Solutions, Inc.
               CHFS 
              
             | 
            
              $ 5.28 | 1.15 % | $ 34.5 M | ||
| 
              
              CryoLife, Inc.
               CRY 
              
             | 
            
              $ 17.84 | -4.14 % | $ 702 M | ||
| 
              
              Sintx Technologies
               SINT 
              
             | 
            
              $ 3.33 | 4.62 % | $ 12.4 M | ||
| 
              
              GenMark Diagnostics, Inc.
               GNMK 
              
             | 
            
              $ 24.04 | - | $ 1.77 B | ||
| 
              
              Soliton, Inc.
               SOLY 
              
             | 
            
              $ 20.12 | -1.42 % | $ 435 M | ||
| 
              
              Hancock Jaffe Laboratories, Inc.
               HJLI 
              
             | 
            
              $ 10.38 | -1.98 % | $ 98.3 M | ||
| 
              
              Itamar Medical Ltd.
               ITMR 
              
             | 
            
              $ 30.65 | 0.03 % | $ 1.58 B | ||
| 
              
              Misonix, Inc.
               MSON 
              
             | 
            
              $ 26.54 | - | $ 462 M | ||
| 
              
              ShockWave Medical
               SWAV 
              
             | 
            
              $ 334.75 | - | $ 12.3 B | ||
| 
              
              SeaSpine Holdings Corporation
               SPNE 
              
             | 
            
              $ 7.16 | 0.28 % | $ 270 M | ||
| 
              
              ViewRay
               VRAY 
              
             | 
            
              $ 2.64 | 1.54 % | $ 468 M | ||
| 
              
              Intersect ENT, Inc.
               XENT 
              
             | 
            
              $ 28.24 | - | $ 955 M | ||
| 
              
              Bruker Corporation
               BRKR 
              
             | 
            
              $ 38.83 | -0.3 % | $ 5.79 K | ||
| 
              
              Axonics Modulation Technologies
               AXNX 
              
             | 
            
              $ 70.98 | - | $ 3.31 B | ||
| 
              
              BIOLASE
               BIOL 
              
             | 
            
              $ 0.13 | -13.19 % | $ 166 K | ||
| 
              
              Integer Holdings Corporation
               ITGR 
              
             | 
            
              $ 66.39 | 2.87 % | $ 2.23 B | ||
| 
              
              Eargo
               EAR 
              
             | 
            
              $ 2.57 | - | $ 10.2 M | ||
| 
              
              Delcath Systems
               DCTH 
              
             | 
            
              $ 9.5 | -3.36 % | $ 271 M | ||
| 
              
              Viemed Healthcare
               VMD 
              
             | 
            
              $ 6.55 | 1.39 % | $ 251 M | ||
| 
              
              SmileDirectClub
               SDC 
              
             | 
            
              $ 0.08 | -53.45 % | $ 9.71 M | ||
| 
              
              Globus Medical
               GMED 
              
             | 
            
              $ 60.86 | 0.78 % | $ 8.26 B | ||
| 
              
              ThermoGenesis Holdings
               THMO 
              
             | 
            
              $ 0.31 | -25.84 % | $ 171 K | ||
| 
              
              Acutus Medical
               AFIB 
              
             | 
            
              $ 0.09 | -26.83 % | $ 2.62 M | ||
| 
              
              ClearPoint Neuro
               CLPT 
              
             | 
            
              $ 19.02 | -18.07 % | $ 514 M | ||
| 
              
              Surgalign Holdings
               SRGA 
              
             | 
            
              $ 0.18 | -32.98 % | $ 1.68 M | ||
| 
              
              Conformis
               CFMS 
              
             | 
            
              $ 2.27 | - | $ 16.4 M | ||
| 
              
              Sientra
               SIEN 
              
             | 
            
              $ 0.18 | -16.59 % | $ 10.3 M | ||
| 
              
              NuVasive
               NUVA 
              
             | 
            
              $ 39.75 | - | $ 2.07 B | ||
| 
              
              Cutera
               CUTR 
              
             | 
            
              $ 0.1 | -10.19 % | $ 1.99 M | ||
| 
              
              Nemaura Medical 
               NMRD 
              
             | 
            
              $ 0.11 | -17.8 % | $ 2.74 M | ||
| 
              
              Vapotherm
               VAPO 
              
             | 
            
              $ 1.27 | 6.72 % | $ 34 M | ||
| 
              
              Beyond Air
               XAIR 
              
             | 
            
              $ 1.94 | -5.83 % | $ 131 M | ||
| 
              
              Xtant Medical Holdings
               XTNT 
              
             | 
            
              $ 0.82 | -6.71 % | $ 110 M | ||
| 
              
              Pulmonx Corporation
               LUNG 
              
             | 
            
              $ 1.81 | -9.5 % | $ 70.8 M |